What You Should Know:
- Tempus, the $10B artificial intelligence and precision medicine company, announced their first multi-omics collaboration with Actuate Therapeutics, in which datasets of different omic groups – genomics, transcriptomics, epigenomics, and others are combined during analysis to improve research and enable new discoveries, including ones that would have been missed with a single method alone.
- This multi-omics approach is being used by Actuate Therapeutics in support
Read More
Oncology Technology Solutions, Services Impacting Patients and Providers
Addressing the Diversity Challenge in Clinical Research Through Patient Advocacy
Diversity is paramount to the success of clinical research, both ethically and scientifically. Without adequate representation of racial and ethnic minorities, investigators lack an understanding of the safety and efficacy of novel treatments within those groups. From a scientific standpoint, an incomplete dataset hinders drug delivery and the development of breakthrough therapies – but from an ethical standpoint, underrepresentation creates a barrier to treatment options for populations that
Read More
Vysioneer & Pfizer Partner on AI-Powered Oncology Clinical Trials
What You Should Know:
- Vysioneer, a provider of applied AI for Oncology, today announced a data-sharing agreement with Pfizer, a global leader in pharmaceuticals. The agreement aims to lay the foundation for the application of AI in oncology clinical trials.
As part of the agreement, Vysioneer gains access to one of Pfizer's oncology clinical trial datasets to apply Vysioneer's advanced machine-learning techniques to facilitate the drug efficacy assessment process, thereby allowing Pfizer
Read More
5 Components of a Patient-Centric eCOA Strategy for Oncology Clinical Trials
In the US alone, an estimated 1.9 million new cases of cancer were diagnosed in 2022, positioning oncology as a key subject of clinical research. Throughout oncology trial development, it is important that stakeholders acknowledge that only patients can fully understand the impact of treatment on their lives. Regulators are now looking beyond clinical indications such as tumor size and delayed disease progression. When evaluating the risks and benefits of treatment, they want to know whether the
Read More
RTLS Can Enhance the Patient Experience, Staff Safety, and Workflow Operations in 2023
Although the healthcare industry has shown significant resilience, the byproduct of the pandemic has amplified staff stressors across all operational and clinical roles. In a study conducted in 2022, more than one-third (34%) of the participating registered nurses (RN) stated that it was likely they would leave bedside nursing by the end of the year. Almost half (44%) cited both burnout and high-stress environments as their main reasons to retire or pursue other careers.
As staff
Read More
Epic, Impact Advisors, Nordic, Chartis Named 2023 Overall Best in KLAS® Awards
What You Should Know:
Epic, Nordic, Impact Advisors and The Chartis Group won the 2023 Overall Best in KLAS® awards. Epic was named the top Overall Software Suite for the thirteenth straight year in 2023 Best in KLAS – Software & Services report, released, which reports on the top vendors for 2022. Epic was also named the top Overall Physician Practice Vendor. Epic won thirteen other Best in KLAS awards in various market segments.
- Impact Advisors tied with Nordic to be a
Read More
Biden Admin Builds on Cancer Moonshot with 13 More Initiatives
What You Should Know:
- One year ago, President Joe Biden and First Lady Jill Biden reignited the Cancer Moonshot, setting an ambitious, achievable goal: to reduce the death rate from cancer by at least 50 percent over the next 25 years, and improve the experience of people and families living with and surviving cancer, ultimately ending cancer as we know it today.
- The Cancer Moonshot has spurred tremendous action across the federal government and from the public and private
Read More
Is AI-Assisted Lung Cancer Diagnosis Right For Your Hospital?
Lung cancer is the leading cause of cancer deaths worldwide, with approximately 1.8 million people dying from this disease each year. Most patients are diagnosed after symptoms have appeared and the disease has progressed to an advanced stage (Stage III or IV), which explains the current worldwide five-year survival rate of just 20 percent. In contrast, the survival rate for small lung tumors that are treated at Stage 1A is as high as 90 percent. This significant difference highlights a critical
Read More
Boosting Clinical Trial Recruitment Requires Humanity – and Technology
Clinical trials should be a time of promise for better patient outcomes, as they explore new ways to potentially help patients suffering from a variety of conditions. Instead, this phase of treatment development is often met with exasperation as patients, researchers, and drug developers deal with the many barriers to clinical trial recruitment and access.
There are two central – and intrinsically linked – problems with the current state of clinical trial recruitment in the U.S.:
Read More
17 Executive Hospital/Health System Predictions to Watch in 2023
Vijay Kedar, Co-Founder and CEO at Tomorrow Health
Health systems will realize their challenges are not transitory but systemic: This year saw health systems facing a myriad of compounding threats – from historic inflation exacerbating their cost structures, front-line clinician burnout driving widespread labor shortages, and increased capacity issues that left patients in hospital facilities one full day longer than in the prior year. As the financial markets turned south, many institutions
Read More
